Oxford, UK – 11 March 2015. OGT, the molecular genetics company, today announced it has been awarded a £1.2m phase two Small Business Research Initiative (SBRI) Healthcare contract. The contract is to develop Next Generation Sequencing (NGS) analysis software, following the successful completion of phase one and an evaluation by Genomics England, UK Department of Health and Innovate UK.
Development of this innovative technology will increase the accuracy and ease of interpreting whole genome genetic variant data by clinicians, supporting more precise treatment decisions. In addition to the analysis of NGS data, the software will integrate a full spectrum of genetic tests, including NGS, Sanger sequencing, microarray and fluorescence in situ hybridisation (FISH). The results of these tests will be put in context via the use of both public and private databases, providing the clinician with prioritised clinically-relevant results. These easy-to-understand reports will support faster diagnosis and better patient care.
The SBRI contract is managed by Genomics England, to support the implementation of the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients by 2017, producing invaluable data to enable scientific discovery and personalise patient treatment. Although the time and cost of sequencing has reduced dramatically, interpretation is currently a major bottleneck. OGT will use the SBRI funding and its considerable experience in genomic data analysis to enable the use of the 100,000 Genomes Project data by clinicians.
OGT was awarded £200k to develop the software in July 2014 during phase one of the initiative. The selection process for phase two involved an assessment of potential patient impact, technological step change and a route to commercialisation, proving OGT as a leader in the field of genomic data interpretation.
James Clough, Executive Vice President Commercial, OGT said: “The award of this £1.2m contract underlines OGT’s position as a leading developer of cutting-edge products for molecular genetics. OGT has customers in over 60 countries worldwide and will use its extensive sales and marketing infrastructure to successfully commercialise the resulting product.”
Professor Tim Hubbard, Head of Genome Analysis at Genomics England commented, “For widespread use of genome sequencing in routine health care the development of accurate and reliable interpretation software is critical. We are encouraged to see new and existing companies developing products and services in this space.”
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs.
Read
OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx detects clinically relevant rearrangements that occur in patients with acute leukaemia, providing a robust, accessible, rapid turnaround test for KMT2Ar detection.
Read
Through this partnership, SureSeq™ NGS panel users can gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
Read
OGT will be moving from plastic packaging to new, sustainable packaging for CytoCell products, an important step forward in our ongoing environmental efforts.
Read
Improving upon existing SureSeq™ technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples
Read
Enables users to replace multiple techniques with a single streamlined NGS process for faster results.
Read
Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
Read
New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
Read
OGT becomes Britain’s distributor for ASI cytogenetic imaging and analysis solutions, enhancing the potential of OGT’s CytoCell® FISH portfolio.
Read
Company demonstrates complete readiness for new EU IVDR and continued confidence in its safe, reliable, high-quality products.
Read
Enhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
Read
Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
Read
New leadership will drive OGT’s mission to improve clinical care by partnering with customers.
Read
CytoCell® University offers extensive FISH expertise and reaffirms commitment to customer support and training.
Read
New integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
Read
In the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.
Read
Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.
Read
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure® v3 vs traditional array design.
Read
Addition of direct-sales territories follows successes across Europe and APAC and provides customers with enhanced local sales and support services.
Read
New content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.
Read
During these unprecedented times, OGT remains committed and ready to support you...
Read
Reinforcing collaboration toward the realisation of genomic medicine in the area of ophthalmic disorders.
Read
Plasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.
Read
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.
Read
SureSeq™ CLL + CNV - comprehensive CLL genomic profiling from a single assay.
Read
CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.
Read
MDSAP certification of new Cambridge facility smooths path to future IVD approvals.
Read
SureSeq™ complete library preparation solution delivers unparalleled data quality.
Read
State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.
Read
Sysmex demonstrates confidence and investment in OGT and the United Kingdom.
Read
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read
This year, OGT was proud to send CytoCell® Product Manager Alex Hobbs to join the team of Sysmex runners representing Sysmex EMEA, APAC and JEA.
Read
Following successful European rollout, more customers to benefit from enhanced local sales and support services.
Read
Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data, helping researchers effortlessly translate cumbersome NGS data into meaningful results.
Read
Customers to benefit from Sysmex’s extensive operational footprint.
Read
Increased NGS content, now covering 120 fully optimised cancer related genes, provides even more flexibility for customisation.
Read
On 1st April 2018 Dr John Anson took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.
Read
Sysmex, a Japanese in vitro diagnostic company, will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain.
Read
New SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results.
Read
Addition of three new sarcoma probes produces largest portfolio on the market.
Read
CytoSure® FH Panels enable streamlined investigation of familial hypercholesterolemia (FH) and customisation of content.
Read
Significant expansion of CytoCell® haematology range underlines OGT's position as the one-stop-shop for high-quality fluorescence in situ hybridisation (FISH) probes.
Read
Launch of SureSeq myPanel™ NGS Custom Cancer Panels provide scientists with completely customised, pre-optimised next generation sequencing (NGS) probe panels relevant to their research.
Read
CytoCell® ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC).
Read
Workshop at ESHG explores the power of exon-focused microarrays in enhancing genetic syndrome research.
Read
Range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua and Chromosome 15 Alpha Satellite Probe Red.
Read
SureSeq™ FFPE DNA Repair Mix has been optimised to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE) derived DNA.
Read
New CE-IVD labelled CytoCell® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit consistently delivers bright, specific signals with minimal background
Read
New CytoSure® Constitutional v3 +LOH array delivers comprehensive genetic analysis of developmental delay disorders, with content covering 502 targeted genes.
Read
License grants Baylor Miraca use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology.
Read
White paper describes the experiences of Dr Tracey Lewis and Dr Emily Farrow with OGT’s CytoSure Medical Research Exome Array.
Read
Strategic realignment of OGT commercial operations to fuel further growth in its high value genomics products portfolio.
Read
Addition of SureSeq™ Ovarian Cancer Panel and SureSeq NGS Library Preparation Kit to OGT's NGS product range.
Read
New additions to the CytoCell® range include-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13, ROS1-GOPC and RET.
Read
The presentation, entitled ‘The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focussed Array Designs’, took place at the ESHG conference in Glasgow, UK.
Read
Panel replaces the existing procedure of sequential analysis of single genes, to reduce the time and cost associated with identifying MPNs, a group of diseases that cause abnormal blood cell production.
Read
Unique CytoSure® Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the Deciphering Developmental Disorders (DDD) study data.
Read
License gives OGT access to data from the Deciphering Developmental Disorders (DDD) study, which will be used to develop its CytoSure® Constitutional v3 range.
Read
OGT teams up with clinical research experts to discuss the role of next generation sequencing (NGS) in cancer medicine.
Read
White paper explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure® ISCA 8x60k platform.
Read
Proprietary OGT microarray technology will allow clinical laboratories to utilise existing microarray equipment to offer in-house NIPT.
Read
Developed with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focussed, enabling the accurate detection of medical research relevant microdeletions and microduplications.
Read
The award recognises OGT’s acquisition of Cambridge-based Cytocell Limited (CytoCell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.
Read
Landmark project has the potential to accelerate the diagnosis of cancer and rare diseases, ultimately supporting patient care and research.
Read
The CytoSure® Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos.
Read
New and existing CytoCell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure.
Read
New 60-gene next generation sequencing (NGS) hybridisation-based enrichment panel offers researchers accurate and reliable solid tumour profiling for both known and novel variants.
Read
New application note details the technical evaluation of two DNA labelling kits, where OGT’s CytoSure® Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.
Read
New white paper provides researchers to discover how, when used alongside sequencing, microarrays play a vital role in delivering accurate detection of point mutations and single exon copy number aberrations.
Read
Innovative new features further facilitate and standardise the data analysis workflow in order to deliver rapid access to meaningful results.
Read
Expanded range of CytoSure™ Molecular Arrays now enables detection of CNV in genes associated with over 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability and neuromuscular disorders, as well as a range of inherited cancers.
Read
Acquisition expands OGT’s genomic medicine offering, with CytoCell’s portfolio of fluorescence in situ hybridisation (FISH) probes complementing OGT’s CytoSure cytogenetics array and NGS products.
Read
Two-year agreement for the supply of oligo-based arrays for cytogenetics covers a consortium of four UK NHS Genetics Labs.
Read
Paper investigates the main strategies employed to optimise target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies.
Read
Award recognises OGT’s collaboration with the Birmingham and Salisbury NHS Regional Genetics Laboratories to develop and launch a 58-gene solid tumour profiling service to advance vital research into personalised cancer care.
Read
New array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb.
Read
Paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods.
Read
New array combines long oligo aCGH probes with fully validated SNP content, providing the superior detection of both CNVs and loss of heterozygosity (LOH) on a single chip.
Read
App note aims to support researchers in navigating a combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH) on a single array.
Read
The licence agreement agreed with the Cancer Cytogenomics Microarray Consortium (CCMC) is to design a whole genome, cancer-specific microarray.
Read
New office enables OGT to provide hands-on technical support and training to its existing US customers, and to take advantage of opportunities to develop the business further.
Read
Database is comprised of more than 10 million oligonucleotide probes designed to the latest release of the human genome.
Read
By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data.
Read
Array combines array comparative genomic hybridisation (aCGH) probes, endorsed by the International Standards for Cytogenomic Arrays (ISCA) Consortium, with fully validated single nucleotide polymorphism (SNP) content.
Read
CytoSure® Haematological Cancer +SNP array is optimised for the study of the haematological malignancies CLL and Multiple Myeloma, as well as MPN and MDS.
Read
Sir Ed becomes one of only four researchers to have received the prize since it was inaugurated in the year 2000.
Read
New DNA microarrays utilise a unique collection of probes for detecting CNVs within genes associated with a variety of rare disease disorders.
Read
Project aims to develop a tumour profiling assay based on targeted panel enrichment and next generation sequencing (NGS).
Read
Product range now includes high-throughput genomic DNA labelling kits and sample tracking spike-ins
Read
Accreditation extends to all data generation and security procedures, and acknowledges that data confidentiality, availability and integrity is carefully managed and controlled.
Read
Groundbreaking CytoSure® ISCA UPD 4 x 180k array allows simultaneous detection of DNA copy number variation (CNV) and whole chromosome uniparental disomy (UPD).
Read
OGT's Oxford, UK headquarters has been certified to BS EN ISO 9001:2008 by the British Standards Institution (BSI), one of the world’s leading certification bodies.
Read
OGT's CytoSure® Interpret Software can now seamlessly transfer aCGH aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform.
Read
The three new powerful arrays focus on disease and syndrome-associated genome regions, in addition to offering whole genome coverage.
Read
CytoSure® Interpret software delivers faster and easier translation of oligo aCGH data into meaningful results.
Read
Featuring a 4x44k format and dense probe coverage of the DMD gene region, this new array offers increased confidence in detecting deletions and duplications within the DMD gene.
Read
The publication published in Nature is entitled ‘Origins and Functional Impact of Copy Number Variation in the Human Genome.’
Read
The Center for Human Genetics at Katholieke Universiteit Leuven, Belgium, has begun assessment of OGT's CytoSure arrays for use in prenatal diagnostic research.
Read
More than 20,000 samples that have been generated by the Wellcome Trust Case Control Consortium have been processed by OGT.
Read
The Genomic DNA Labelling Kit offers a fast and simple protocol and is optimised for OGT’s CytoSure® family of high resolution oligonucleotide arrays.
Read
OGT and Wellcome Trust Sanger Institute sign collaboration agreement to develop a single platform microarray to test for genetic defects in unborn children.
Read
Visit USA site
Visit Canada site
